-
平臺編號：bio-133044
-
細胞信息： I 2.1
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
用途：/
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
I 2.1（人急性淋巴細胞白血病細胞）
I 2.1（人急性淋巴細胞白血病細胞）
產(chǎn)品類別：人源細胞系
生長特性：貼壁生長
細胞形態(tài)：lymphoblast
凍存條件：90%FBS+10%DMSO
Synonyms: I 2.1(人急性淋巴細胞白血病細胞)
Background: The I 2.1 cell line is a FADD mutant of the wild-type Jurkat cell line A3 (see ATCC -CRL-2570). Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. Ref
ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. Ref Two of these ICR-191 treated clones have been deposited at the ATCC . They are I 9.2 (ATCC CRL-2571), a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2.1 (ATCC CRL-2572), a clone with a mutation in the adaptor FADD.
Species: Homo sapiens, human
Disease: acute T cell leukemia
Gender: male
Morphology: lymphoblast
Growth Mode: suspension
DNA Profile: Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 8,11
D16S539: 11
D5S818: 9
D7S820: 8,10
THO1: 6,9.3
TPOX: 8,10
vWA: 17,18
Cell Line Authentication Service
Culture Medium: RPMI-1640+15%FBS
We strongly suggest to purchase the complete medium
Cryopreservation medium: 90%FBS+10%DMSO
Comments: Unlike the parental line A3 that does express FADD, the I 2.1 cell line does not express FADD protein by immunoblot analysis and is completely resistant to Fas-induced death. Complementation of the I 2.1 cell lines with wild-type FADD restores Fas-mediated apoptosis. Fas activation of caspase-2, caspase-3, caspase-7, and caspase-8 is completely defective in the FADD mutant cell line I 2.1. Ref
This cell line can be used to study the role of FADD in apoptotic signaling pathways in the absence of overxpression.
產(chǎn)品類別：人源細胞系
生長特性：貼壁生長
細胞形態(tài)：lymphoblast
凍存條件：90%FBS+10%DMSO
Synonyms: I 2.1(人急性淋巴細胞白血病細胞)
Background: The I 2.1 cell line is a FADD mutant of the wild-type Jurkat cell line A3 (see ATCC -CRL-2570). Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. Ref
ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. Ref Two of these ICR-191 treated clones have been deposited at the ATCC . They are I 9.2 (ATCC CRL-2571), a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2.1 (ATCC CRL-2572), a clone with a mutation in the adaptor FADD.
Species: Homo sapiens, human
Disease: acute T cell leukemia
Gender: male
Morphology: lymphoblast
Growth Mode: suspension
DNA Profile: Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 8,11
D16S539: 11
D5S818: 9
D7S820: 8,10
THO1: 6,9.3
TPOX: 8,10
vWA: 17,18
Cell Line Authentication Service
Culture Medium: RPMI-1640+15%FBS
We strongly suggest to purchase the complete medium
Cryopreservation medium: 90%FBS+10%DMSO
Comments: Unlike the parental line A3 that does express FADD, the I 2.1 cell line does not express FADD protein by immunoblot analysis and is completely resistant to Fas-induced death. Complementation of the I 2.1 cell lines with wild-type FADD restores Fas-mediated apoptosis. Fas activation of caspase-2, caspase-3, caspase-7, and caspase-8 is completely defective in the FADD mutant cell line I 2.1. Ref
This cell line can be used to study the role of FADD in apoptotic signaling pathways in the absence of overxpression.
